Literature DB >> 20856722

Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.

David Cella1, Joseph C Cappelleri, Andrew Bushmakin, Claudie Charbonneau, Jim Z Li, Sindy T Kim, Isan Chen, M Dror Michaelson, Robert J Motzer.   

Abstract

In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival when compared with interferon alfa as first-line therapy in patients with metastatic renal cell carcinoma. This article investigates whether baseline quality of life and demographic and clinical variables were predictive for progression-free survival.

Entities:  

Year:  2009        PMID： 20856722      PMCID： PMC2790652          DOI： 10.1200/JOP.0922004

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  22 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?

Authors:  A G E M de Boer; J J B van Lanschot; P F M Stalmeier; J W van Sandick; J B F Hulscher; J C J M de Haes; M A G Sprangers
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

3.  Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

Authors:  F Efficace; L Biganzoli; M Piccart; C Coens; K Van Steen; T Cufer; R E Coleman; H A Calvert; T Gamucci; C Twelves; P Fargeot; A Bottomley
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

Review 4.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

5.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

6.  Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

Authors:  David Cella; Susan Yount; Hongyan Du; Rahul Dhanda; Kathleen Gondek; Katie Langefeld; Jacquelyn George; William P Bro; Celeste Kelly; Ronald Bukowski
Journal:  J Support Oncol       Date:  2006-04

7.  Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

Authors:  Bradley J Monk; Helen Q Huang; David Cella; Harry J Long
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

8.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

9.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

10.  Can patient satisfaction with quality of life predict survival in advanced colorectal cancer?

Authors:  Christopher G Lis; Digant Gupta; Joel Granick; James F Grutsch
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.359
View more
  18 in total

Review 1.  Urine metabolomics for kidney cancer detection and biomarker discovery.

Authors:  Sheila Ganti; Robert H Weiss
Journal:  Urol Oncol       Date:  2011 Sep-Oct       Impact factor: 3.498

2.  Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.

Authors:  David Cella; Robert J Motzer; Brian I Rini; Joseph C Cappelleri; Krishnan Ramaswamy; Subramanian Hariharan; Bhakti Arondekar; Andrew G Bushmakin
Journal:  Value Health       Date:  2018-05-11       Impact factor: 5.725

3.  Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.

Authors:  B K Hamilton; A D Law; L Rybicki; D Abounader; J Dabney; R Dean; H K Duong; A T Gerds; R Hanna; B T Hill; D Jagadeesh; M E Kalaycio; C Lawrence; L McLellan; B Pohlman; R M Sobecks; B J Bolwell; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

4.  Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.

Authors:  Aaron Vinik; Andrew Bottomley; Beata Korytowsky; Yung-Jue Bang; Jean-Luc Raoul; Juan W Valle; Peter Metrakos; Dieter Hörsch; Rajiv Mundayat; Arlene Reisman; Zhixiao Wang; Richard C Chao; Eric Raymond
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

5.  Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.

Authors:  Courtney Carmichael; Bertram E Yuh; Virginia Sun; Clayton Lau; Joann Hsu; Junmi Saikia; Xueli Liu; Timothy Wilson; Betty Ferrell; Sumanta Kumar Pal
Journal:  Clin Genitourin Cancer       Date:  2012-10-09       Impact factor: 2.872

6.  Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.

Authors:  Peter C Trask; Andrew G Bushmakin; Joseph C Cappelleri; Jamal Tarazi; Brad Rosbrook; Paul Bycott; Sinil Kim; Walter M Stadler; Brian Rini
Journal:  J Cancer Surviv       Date:  2011-04-07       Impact factor: 4.442

7.  Predictors of health-related quality of life and association with survival may identify colorectal cancer patients at high risk of poor prognosis.

Authors:  Monica E Reyes; Yuanqing Ye; Yeling Zhou; Alexander Liang; Scott Kopetz; M Alma Rodriquez; Xifeng Wu; Michelle A T Hildebrandt
Journal:  Qual Life Res       Date:  2016-08-04       Impact factor: 4.147

8.  MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma.

Authors:  Elizabeth Ellen Jones; Thomas W Powers; Benjamin A Neely; Lisa H Cazares; Dean A Troyer; Alexander S Parker; Richard R Drake
Journal:  Proteomics       Date:  2014-03-03       Impact factor: 3.984

9.  The role of patient-physician relationship on health-related quality of life and pain in cancer patients.

Authors:  Cleo A Samuel; Olive Mbah; Jennifer Schaal; Eugenia Eng; Kristin Z Black; Stephanie Baker; Katrina R Ellis; Fatima Guerrab; Lauren Jordan; Alexandra F Lightfoot; Linda B Robertson; Christina M Yongue; Samuel Cykert
Journal:  Support Care Cancer       Date:  2019-10-16       Impact factor: 3.603

Review 10.  Targeted therapy for advanced renal cell carcinoma.

Authors:  C Coppin; L Le; F Porzsolt; T Wilt
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.